RARE Daily

Castle Creek Raises $75 Million to Advance Gene Therapy Programs

March 25, 2020

Rare Daily Staff

Castle Creek Biosciences said it completed a $75 million financing that will be used to advance and expand its gene therapy pipeline and expand its manufacturing capacity.

Paragon Biosciences led a $55 million equity investment with participation from Fidelity Management & Research Company and Valor Equity Partners. In addition, Horizon Technology Finance Corporation provided a $20 million venture loan.

Castle Creek Biosciences most advanced product candidate is FCX-007, an experimental gene therapy in late-stage development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a severe skin disease characterized by very fragile skin that is prone to chronic blistering and wounds from normal friction or irritation.

RDEB impacts children from birth and has a high mortality rate. There are currently no approved treatment options for RDEB.

John Maslowski, Chief Executive Officer of Castle Creek Biosciences

Stay Connected

Sign up for updates straight to your inbox.